"Obicetrapib offers a promising new option — not only did it lower LDL cholesterol by over 30%, but we also saw a reduction in lipoprotein(a)"❗ Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. Obicetrapib is a highly selective cholesteryl ester transfer protein inhibitor that reduces low-density lipoprotein (LDL) cholesterol levels https://www.nejm.org/doi/10.1056/NEJMoa2415820 A clinical trial tested a once-daily oral medication called Obicetrapib, and found it significantly lowered both LDL cholesterol and lipoprotein(a), [Lp(a)], two key contributors to cardiovascular disease https://medicalxpress.com/news/2025-05-cholesterol-pill-high-heart.html